Radiotherapy equipment and departments in the European countries: Final results from the ESTRO-HERO survey

被引:135
|
作者
Grau, Cai [1 ]
Defourny, Noemie [2 ]
Malicki, Julian [3 ]
Dunscombe, Peter [4 ]
Borras, Josep M. [5 ]
Coffey, Mary [6 ]
Slotman, Ben [7 ]
Bogusz, Marta [8 ]
Gasparotto, Chiara [2 ]
Lievens, Yolande [9 ]
机构
[1] Aarhus Univ Hosp, DK-8000 Aarhus C, Denmark
[2] European Soc Radiotherapy & Oncol, Brussels, Belgium
[3] Univ Med Sci, Greater Poland Canc Ctr, Poznan, Poland
[4] Univ Calgary, Calgary, AB T2N 1N4, Canada
[5] Univ Barcelona, E-08007 Barcelona, Spain
[6] Univ Dublin Trinity Coll, Dublin 2, Ireland
[7] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[8] Canc Diag & Treatment Ctr, Katowice, Poland
[9] Ghent Univ Hosp, Ghent, Belgium
关键词
Radiotherapy equipment; Health economics; RADIATION-THERAPY IMRT; PHASE-II; GUIDELINES; CANCER; COST; INFRASTRUCTURE; CAPACITY; QUARTS; VOLUME; MODEL;
D O I
10.1016/j.radonc.2014.08.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Documenting the distribution of radiotherapy departments and the availability of radiotherapy equipment in the European countries is an important part of HERO - the ESTRO Health Economics in Radiation Oncology project. HERO has the overall aim to develop a knowledge base of the provision of radiotherapy in Europe and build a model for health economic evaluation of radiation treatments at the European level. The aim of the current report is to describe the distribution of radiotherapy equipment in European countries. Methods: An 84-item questionnaire was sent out to European countries, principally through their national societies. The current report includes a detailed analysis of radiotherapy departments and equipment (questionnaire items 26-29), analyzed in relation to the annual number of treatment courses and the socio-economic status of the countries. The analysis is based on validated responses from 28 of the 40 European countries defined by the European Cancer Observatory (ECO). Results: A large variation between countries was found for most parameters studied. There were 2192 linear accelerators, 96 dedicated stereotactic machines, and 77 cobalt machines reported in the 27 countries where this information was available. A total of 12 countries had at least one cobalt machine in use. There was a median of 0.5 simulator per MV unit (range 0.3-1.5) and 1.4 (range 0.4-4.4) simulators per department. Of the 874 simulators, a total of 654 (75%) were capable of 3D imaging (CT-scanner or CBCT-option). The number of MV machines (cobalt, linear accelerators, and dedicated stereotactic machines) per million inhabitants ranged from 1.4 to 9.5 (median 5.3) and the average number of MV machines per department from 0.9 to 8.2 (median 2.6). The average number of treatment courses per year per MV machine varied from 262 to 1061 (median 419). While 69% of MV units were capable of IMRT only 49% were equipped for image guidance (IGRT). There was a clear relation between socio-economic status, as measured by GNI per capita, and availability of radiotherapy equipment in the countries. In many low income countries in Southern and Central-Eastern Europe there was very limited access to radiotherapy and especially to equipment for IMRT or IGRT. Conclusions: The European average number of MV machines per million inhabitants and per department is now better in line with QUARTS recommendations from 2005, but the survey also showed a significant heterogeneity in the access to modern radiotherapy equipment in Europe. High income countries especially in Northern-Western Europe are well-served with radiotherapy resources, other countries are facing important shortages of both equipment in general and especially machines capable of delivering high precision conformal treatments (IMRT, IGRT). (C) 2014 Elsevier Ireland Ltd.
引用
收藏
页码:155 / 164
页数:10
相关论文
共 50 条
  • [1] Radiotherapy departments and equipment in the European countries: Final results from the ESTRO-HERO survey
    Grau, C.
    Defourney, N.
    Malicki, J.
    Dunscombe, P.
    Borras, J. M.
    Coffey, M.
    Slotman, B.
    Bogusz, M.
    Gasparotto, C.
    Lievens, Y.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S222 - S222
  • [2] Radiotherapy staffing in the European countries: Final results from the ESTRO-HERO survey
    Lievens, Yolande
    Defourny, Noemie
    Coffey, Mary
    Borras, Josep M.
    Dunscombe, Peter
    Slotman, Ben
    Malicki, Julian
    Bogusz, Marta
    Gasparotto, Chiara
    Grau, Cai
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 112 (02) : 178 - 186
  • [3] Radiotherapy staffing in the European countries: Final results from the ESTRO-HERO survey
    Lievens, Y.
    Coffey, M.
    Defourney, N.
    Dunscombe, P.
    Borras, J.
    Slotman, B.
    Malicki, J.
    Bogusz, M.
    Gasparotto, C.
    Grau, C.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S222 - S223
  • [4] Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey
    Dunscombe, Peter
    Grau, Cai
    Defourny, Noemie
    Malicki, Julian
    Borras, Josep M.
    Coffey, Mary
    Bogusz, Marta
    Gasparotto, Chiara
    Slotman, Ben
    Lievens, Yolande
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 112 (02) : 165 - 177
  • [5] The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis
    Borras, Josep M.
    Lievens, Yolande
    Dunscombe, Peter
    Coffey, Mary
    Malicki, Julian
    Corral, Julieta
    Gasparotto, Chiara
    Defourny, Noemie
    Barton, Michael
    Verhoeven, Rob
    van Eycken, Liesbeth
    Primic-Zakelj, Maja
    Trojanowski, Maciej
    Strojan, Primoz
    Grau, Cai
    Kokobobo, Arianit
    Sedlmayer, Felix
    De Hertogh, Olivier
    Hadjieva, Tatiana
    Petera, Jiri
    Eriksen, Jesper Grau
    Jaal, Jana
    Azria, David
    Takacsi-Nagy, Zoltan
    Johannsson, Jakob
    Cunningham, Moya
    Atkocius, Vydmantas
    Untereiner, Michel
    Pirotta, Martin
    Karadjinovic, Vanja
    Levernes, Sverre
    Skladowski, Krystof
    Trigo, Maria Lurdes
    Segedin, Barbara
    Cabezas, Sonia Garcia
    Lagerlund, Magnus
    Pastoors, Bert
    Slotman, Ben
    Beardmore, Charlotte
    Smyth, Gaile
    Vaarkamp, Jaap
    Dyzmann-Sroka, Agnieszka
    Kubiak, Anna
    Henau, Kris
    Lemmens, Valery
    [J]. RADIOTHERAPY AND ONCOLOGY, 2015, 116 (01) : 38 - 44
  • [6] Estimating the number of fractions by tumour site for European countries in 2012 and 2025: An ESTRO-HERO analysis
    Borras, Josep M.
    Grau, Cai
    Corral, Julieta
    Wong, Karen
    Barton, Michael B.
    Ferlay, Jacques
    Bray, Freddie
    Lievens, Yolande
    [J]. RADIOTHERAPY AND ONCOLOGY, 2018, 126 (02) : 198 - 204
  • [7] National costs & resource requirements of radiotherapy: costing estimate from the ESTRO-HERO project
    Roques, T.
    Spencer, K.
    Defourny, N.
    Diez, P.
    Francis, A.
    Griffin, S.
    Langmack, K.
    Kirkby, N.
    Mee, T.
    Roe, C.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S811 - S811
  • [8] Value-based radiotherapy: A new chapter of the ESTRO-HERO project
    Lievens, Yolande
    Borras, Josep-Maria
    Grau, Cai
    Aggarwal, Ajay
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 160 : 236 - 239
  • [9] Cost of the external beam radiotherapy in Catalonia (Spain): an application of the ESTRO-HERO model
    Corral, J.
    Algara, M.
    Munoz-Montplet, C.
    Eraso, A.
    Giralt, J.
    Espinas, J. A.
    Sola, J.
    Defourny, N.
    Lievens, Y.
    Borras, J. M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S30 - S32
  • [10] Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis
    Defourny, Noemie
    Dunscombe, Peter
    Perrier, Lionel
    Grau, Cai
    Lievens, Yolande
    [J]. RADIOTHERAPY AND ONCOLOGY, 2016, 121 (03) : 468 - 474